Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
   PubMed Web of Science ®Google Scholar
• Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–4544.
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nature Rev Cancer. 2017;17:725–737.
   PubMed Web of Science ®Google Scholar
• Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep. 1973;4:31–42.
   Google Scholar
• Nicholson AG, Chansky K, Crowley J, et al. The international association for the study of lung cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:300–311.
   PubMed Web of Science ®Google Scholar
• Kalemkerian GP. Small cell lung cancer. Semin Respir Crit Care Med. 2016;37:783–795.
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczensna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;279:2220–2229.
   Google Scholar
• Owonikoko TK, Behera M, Chen Z, et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thoracic Oncol. 2012;7:866–872.
   PubMed Web of Science ®Google Scholar
• Iams WT, Porter J, Horn L. Immunotherapeutic approaches for small-cell lung cancer. Nat Rev Clin Oncol. 2020;17:300–313.
   PubMed Web of Science ®Google Scholar
• Calles A, Aguado G, Sandoval C, et al. The role of immunotherapy in small cell lung cancer. Clin Tranl Oncol. 2019;21:961–976.
   PubMed Web of Science ®Google Scholar
• Lally BE, Urbanic JJ, Blackstock AW, et al. Small cell lung cancer: have we made any progress over the last 25 years. Oncologist. 2007;12:1096–1104.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in the first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929–1939.
   PubMed Web of Science ®Google Scholar
• Bunn PA, Minna D, Augustyn A, et al. Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes? J Thorac Oncol. 2016;11:453–474.
   PubMed Web of Science ®Google Scholar
• Schneider BJ, Kalemkerian GP. Personalized therapy of small cell lung cancer. In: Ahmad A, Gadgeel SM, editors. Lung cancer and personalized medicine: novel therapies and clinical management. New York: Springer; 2016. p. 149–174.
   Google Scholar
• Amini A, Byers LA, Welsh JW, et al. Progress in the management of limited-stage small cell lung cancer. Cancer. 2014;120:790–798.
   PubMed Web of Science ®Google Scholar
• Auperin A, Arriagada R, Pignon JP, et al.; Prophylactic Cranial Irradiation Overview Collaborative Group. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999;341:476–484.
   PubMed Web of Science ®Google Scholar
• Rossi A, DiMaio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30:1692–1698.
   PubMed Web of Science ®Google Scholar
• Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised clinical trial. Lancet. 2015;385:36–42.
   PubMed Web of Science ®Google Scholar
• Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–672.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:663–671.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Kazarnowicz A, Karaseva N, et al. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer: (IMpower133): a randomised phase I/III trial. Ann Oncol. 2020;31:310–317.
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, Dvorkin M, Chen Y, et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC: updated results from the phase III CASPIAN study [abstract]. J Clin Oncol. 2020;38(suppl 15):9002.
   Web of Science ®Google Scholar
• Gong J, Salgia R. Managing patients with relapsed small-cell lung cancer. J Oncol Pract. 2018;14:359–366.
   PubMed Web of Science ®Google Scholar
• Von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658–667.
   PubMed Web of Science ®Google Scholar
• O’Brien MER, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24:5441–5447.
   PubMed Web of Science ®Google Scholar
• Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21:645–654.
   PubMed Web of Science ®Google Scholar
• von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small cell lung cancer. J Clin Oncol. 2014;32:4012–4019.
   PubMed Web of Science ®Google Scholar
• Ready N, Farago AF, de Braud F, et al. Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol. 2019;14:237–244.
   PubMed Web of Science ®Google Scholar
• Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer: results from the KEYNOTE-028 and KEYNOTE-158 studies [abstract]. Proc AACR. 2019. DOI:10.1158/1538-7445.AM2019-CT073
   Google Scholar
• World Health Organization [ Internet]. [cited 2020 Apr 7]. Available from: https://gco.iarc.fr/today/home
   Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–1833.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–2092.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040–2051.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–2301.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–1550.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–265.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342–2350.
   PubMed Web of Science ®Google Scholar
• Sabari JK, Lok BH, Laird J, et al. Unraveling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14:549–561.
   PubMed Web of Science ®Google Scholar
• George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524:47–53.
   PubMed Web of Science ®Google Scholar
• Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2:798–811.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nature Rev Cancer. 2019;19:289–297.
   PubMed Web of Science ®Google Scholar
• Gianchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev. 2013;12:1091–1100.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–242.
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847–856.
   PubMed Web of Science ®Google Scholar
• Oizumi S, Yoh K, Matsumoto S, et al. Assessment of PD-L1 expression and oncogenic gene status in patients with small-cell lung cancer: immuno-oncology biomarker study in LC-SCRUM-Japan [abstract]. J Clin Oncol. 2019;37(15S):471s.
   PubMedGoogle Scholar
• Nirschl CJ, Drake CG. Coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res. 2013;19:4917–4924.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–133.
   PubMed Web of Science ®Google Scholar
• Iams WT, Shiuan E, Meador CB, et al. Improved prognosis and increased tumor-infiltrating lymphocytes in patients who have SCLC with neurologic paraneoplastic syndromes. J Thorac Oncol. 2019;14:1970–1981.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69–74.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500–2501.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Nathanson T, Rizvi H, et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell. 2018;33:843–852.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–128.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Callahan MK, Awad MM, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell. 2018;33:853–861.
   PubMed Web of Science ®Google Scholar
• Doyle A, Martin W, Funa K, et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med. 1985;161:1135–1151.
   PubMed Web of Science ®Google Scholar
• He Y, Rozeboom L, Rivard CJ, et al. MHC class II expression in lung cancer. Lung Cancer. 2017;112:75–80.
   PubMed Web of Science ®Google Scholar
• Schalper KA, Carvajal-Hausdorf DE, McLaughlin JF, et al. Objective measurement and significance of PD-L1, B7-H3, B7-H4, and TILs in small cell lung cancer [abstract]. J Clin Oncol. 2016;34(15S):451s.
   Google Scholar
• Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369–2379.
   PubMed Web of Science ®Google Scholar
• Leal T, Wang Y, Dowlati A, et al. Randomized phase II clinical trial of cisplatin/carboplatin and etoposide alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer: ECOG-ACRIN EA5161 [abstract]. J Clin Oncol. 2020;38(suppl 15):9000.
   Google Scholar
• Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24:75–83.
   PubMed Web of Science ®Google Scholar
• Reck M, Luft A, Szczensa A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34:3740–3748.
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Kim HR, Govindan R, et al., Nivolumab plus ipilimumab, nivo, or placebo as maintenance therapy in patients with extensive disease small cell lung cancer after first-line platinum-based chemotherapy: results from the double-blind, randomized phase III CheckMate 451 study [abstract]. Ann Oncol. 2019;30(suppl2):ii77–ii80.
   Google Scholar
• Gadgeel SM, Pennell NA, Fidler MJ, et al. Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer. J Thorac Oncol. 2018;13:1393–1399.
   PubMed Web of Science ®Google Scholar
• Welsh JW, Heymach JV, Chen D, et al. Phase I trial of pembrolizumab and radiation therapy after induction chemotherapy for extensive-stage small cell lung cancer. J Thorac Oncol. 2020;15:266–273.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:883–895.
   PubMed Web of Science ®Google Scholar
• Ready NE, Ott PA, Hellman MD, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort. J Thorac Oncol. 2020;15:426–435.
   PubMed Web of Science ®Google Scholar
• Reck M, Vincente D, Ciuleanu T, et al., Efficacy and safety of nivolumab monotherapy versus chemotherapy in recurrent small cell lung cancer: results from CheckMate 331 [abstract]. Ann Oncol. 2018;29(suppl 10):x39–x43.
   Google Scholar
• Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study. J Clin Oncol. 2017;35:3823–3829.
   PubMed Web of Science ®Google Scholar
• Chung HC, Lopez-Martin JA, Kao SCH, et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer: KEYNOTE-158 [abstract]. J Clin Oncol. 2018;36(15S):439s.
   Google Scholar
• Pujol JL, Greillier L, Audigier-Valette C, et al. A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: results from the IFCT-1603 trial. J Thorac Oncol. 2019;14:903–913.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Chiang A, Gilbert J, et al. Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab trial in extensive-stage small cell lung cancer [abstract]. Ann Oncol. 2016;27(suppl6):vi493–vi496.
   Google Scholar
• Bondarenko I, Juan-Vidal O, Pajkos G, et al. Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase ii BALTIC study [abstract]. Ann Oncol. 2018;29(suppl8):viii596–viii602.
   Google Scholar
• Sen T, Rodriguez BL, Chen L, et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019;9:646–661.
   PubMed Web of Science ®Google Scholar
• Krebs M, Ross K, Kim S, et al. An open-label, multitumor phase II basket study of olaparib and durvalumab (MEDIOLA): results in patients with relapsed SCLC [abstract]. J Thorac Oncol. 2017;12(suppl 2):S2044.
   Google Scholar
• Thomas A, Vilimas R, Tindade C, et al. Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a phase II study. J Thorac Oncol. 2019;14:1447–1457.
   PubMed Web of Science ®Google Scholar
• McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer. JAMA Oncol. 2016;2:46–54.
   PubMed Web of Science ®Google Scholar
• Büttner R, Gosney JR, Skov BG, et al. Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol. 2017;35:3867–3876.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC comparison project. J Thorac Oncol. 2017;12:208–222.
   PubMed Web of Science ®Google Scholar
• Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. 2018;13:1302–1311.
   PubMed Web of Science ®Google Scholar
• Vokes NI, Liu D, Ricciuti B, et al. Harmonization of tumor mutational burden quantification and association with response to immune checkpoint blockade in non-small-cell lung cancer. JCO Precis Oncol. 2019. DOI:10.1200/PO.19.00171
   PubMed Web of Science ®Google Scholar
• Addeo A, Banna GL, Weiss GJ. Tumor mutational burden – from hopes to doubts. JAMA Oncol. 2019;5:934–935.
   PubMed Web of Science ®Google Scholar
• Ott PA, Bang YJ, Piha-Paul SA, et al. T-cell inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2018;37:318–327.
   PubMed Web of Science ®Google Scholar
• Mezquita L, Auclin E, Ferrara R, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4:351–357.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Gong Y, Keegan P, et al. Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer. JAMA Oncol. 2019;5:1481–1485.
   PubMed Web of Science ®Google Scholar
• Sorich MJ, Rowland A, Karapetis CS, et al. Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for NSCLC: pooled analysis of clinical trials. J Thorac Oncol. 2019;14:1440–1446.
   PubMed Web of Science ®Google Scholar
• Wang W, Hodkinson P, McLaren F, et al. Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate. Int J Cancer. 2012;131:E928–937.
   PubMed Web of Science ®Google Scholar
• Ganesan A-P, Johansson M, Ruffell B, et al. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol. 2013;191:2009–2017.
   PubMed Web of Science ®Google Scholar
• Fang W, Ma Y, Yin JC, et al. Comprehensive genomic profiling identifies novel genetic predictors of response to anti-PD-(L)1 therapies in non-small-cell lung cancer. Clin Cancer Res. 2019;25:5015–5026.
   PubMed Web of Science ®Google Scholar
• Naylor SL, Johnson BE, Minna JD, et al. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature. 1987;329:451–454.
   PubMed Web of Science ®Google Scholar
• Brauch H, Johnson B, Hovis J, et al. Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. N Engl J Med. 1987;317:1109–1113.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan R, Huang C, Cho H-I, et al. Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res. 2012;72:5483–5493.
   PubMed Web of Science ®Google Scholar
• Seute T, Leffers P, Velde GP, et al. Detection of brain metastases from small cell lung cancer. Cancer. 2008;112:1827–1834.
   PubMed Web of Science ®Google Scholar
• Hendriks LE, Henon C, Auclin E, et al. Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thorac Oncol. 2019;14:1244–1254.
   PubMed Web of Science ®Google Scholar
• Turner DC, Kondic AG, Anderson KM, et al. Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance. Clin Cancer Res. 2018;24:5841–5849.
   PubMed Web of Science ®Google Scholar